Exane Derivatives’s Viavi Solutions VIAV Stock Holding History

Exane Derivatives’s Portfolio VIAV Stock Details VIAV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-12,976	Closed	-$209K	–	981
2022 Q1	$209K	Buy	+12,976	New	+$214K	0.06%	319
2021 Q4	–	Sell	-14,674	Closed	-$231K	–	1033
2021 Q3	$231K	Buy	14,674 +3,050	+26%	+$50K	0.06%	360
2021 Q2	$200K	Buy	+11,624	New	+$196K	0.05%	388

Other funds holding VIAV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

WHG

Westwood Holdings Group Dallas, Texas $13.3B AUM 29.38% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Exane Derivatives's VIAV Position: Q2 2022 in Review

Exane Derivatives sold out of Viavi Solutions (VIAV) in Q2 2022, closing a stake of 12,976 shares — an estimated $209K sold.

Exane Derivatives first reported a position in VIAV in Q2 2021 and held it in 3 quarters. The position peaked at $231K in Q3 2021. 312 funds tracked by Wall St. Rank hold VIAV as of Q2 2022.

Exane Derivatives reported no remaining Viavi Solutions position as of Q2 2022 after selling out during the quarter.
Exane Derivatives sold 12,976 Viavi Solutions shares in Q2 2022, an estimated $209K.
Exane Derivatives first reported a position in Viavi Solutions in Q2 2021 and held it in 3 quarters.
Exane Derivatives's Viavi Solutions position peaked at $231K in Q3 2021.
312 funds tracked by Wall St. Rank held Viavi Solutions as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.